Health Canada’s non-compliance notice may delay DRL’s semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday
​Health Canada’s non-compliance notice may delay DRL’s semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday by Soban News (international And National News)
